Abstract: A compound including a ligand having the formula: or is disclosed. In these formulas, each R1, R2, and R3 is independently selected from hydrogen, alkyl, and aryl; at least one of R1 and R2 is a branched alkyl containing at least 4 carbon atoms, where the branching occurs at a position further than the benzylic position; where R1 and R3 are mono-, di-, tri-, tetra-, or no substitutions; and R2 is mono-, di-, or no substitutions. Heteroleptic iridium complexes including such compounds, and devices including such compounds are also disclosed.

Abstract: Method, system, device and medium for determining a blood flow velocity in a vessel are provided. An example method includes receiving a 3D model of the vessel, which is reconstructed based on X-ray angiography images of the vessel. The method further includes specifying a segment of the 3D model by a start landmark and a termination landmark. Moreover, the method includes determining the blood flow velocity based on length of the segment and perfusion time for the segment by normalizing the blood flow velocity to correspond to a cardiac cycle. The method has a better accuracy in calculating blood flow velocity, and requires no additional modalities other than the original X-ray angiogram sequences used to visualize coronary arteries.

Abstract: This invention relates to the development of heterocyclic materials with high triplet excitation energy, which can be used as host materials in electroluminescent devices such as a PHOLED. The materials improve the performance of such devices by enhancing the lifetime and efficiency of the device when the newly developed heterocyclic materials are utilized as a host.

Abstract: A novel composition formed of a first compound is disclosed where the first compound is selected from

Abstract: The present disclosure relates to a device, a system, and a computer-readable medium for calculating vessel flow parameters based on angiography. In one implementation, the device includes a processor and a memory storing computer-executable instructions that, when executed by the processor, cause the processor to perform the following operations: selecting a plurality of template frames from the angiographic images to generate a 3D model for a vessel; determining a start frame and an end frame in the plurality of angiographic images showing a contrast filling process; determining corresponding locations of front ends of the contrast in the start frame and the end frame in the 3D model of the vessel; calculating a vessel volume between the determined locations of the front ends in the 3D model; and determining an average blood flow rate based on the calculated volume, and a time interval between the start frame and the end frame.

Abstract: Compounds of formula (I) or (II) can modulate the activity of S1P receptors.

Abstract: Example nanoparticles may include an iron-based core, and a shell. The shell may include a non-magnetic, anti-ferromagnetic, or ferrimagnetic material. Example alloy compositions may include an iron-based grain, and a grain boundary. The grain boundary may include a non-magnetic, anti-ferromagnetic, or ferrimagnetic material. Example techniques for forming iron-based core-shell nanoparticles may include depositing a shell on an iron-based core. The depositing may include immersing the iron-based core in a salt composition for a predetermined period of time. The depositing may include milling the iron-based core with a salt composition for a predetermined period of time. Example techniques for treating a composition comprising core-shell nanoparticles may include nitriding the composition.

Abstract: The disclosure is directed to an iron-nitride material having a polycrystalline microstructure including a plurality of elongated crystallographic grains with grain boundaries, the iron-nitride material including at least one of an ??-Fe16N2 phase and a body-center-tetragonal (bct) phase comprising Fe and N. The disclosure is also directed a method producing an iron-nitride material.

Abstract: Novel phosphorescent metal complexes containing 2-phenylisoquinoline ligands with at least two substituents on the isoquinoline ring are provided. The disclosed compounds have low sublimation temperatures that allow for ease of purification and fabrication into a variety of OLED devices.

Abstract: Disclosed is a connection structure of an exhaust bearing seat for compressors and screw compressors, designed to solve the problem of large radial vibration of the existing exhaust-end bearing seat. The connection structure includes an exhaust bearing seat, an oil separation bucket, and an oil separation screen assembly all arranged at an exhaust end of a body of the compressor, wherein a tail end of the exhaust bearing seat is connected with the oil separation screen assembly, and an outer periphery of the oil separation screen assembly is provided with a vibration-reducing element, which is connected to an inner wall of the oil separation bucket. The vibration of the exhaust bearing seat is transmitted to the vibration-reducing element through the oil separation screen assembly, and then to the oil separation bucket after being absorbed and suppressed by the vibration-reducing element.

Abstract: Provided are tetrahydroisoquinoline derivatives as Nrf2 activators.

Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.

Abstract: The present disclosure relates to a method, storage medium, and system for analyzing an image sequence of a periodic physiological activity. In one implementation, the method includes receiving the image sequence acquired by an imaging device, the image sequence having a plurality of frames and determining local motions for pixels in each frame of the image sequence. The local motion for a pixel may be determined using corresponding pixels in frames adjacent to the frame to which the pixel belongs. The method further includes determining principal motions for the plurality of frames based on the local motions; determining a motion magnitude profile based on the principal motions; and determining the phase of each frame in the image sequence based on the motion magnitude profile.

Abstract: This invention discloses novel polycyclic heteroaromatic compound core structures. These compounds can be used as hosts for PHOLEDs.

Abstract: A compound including a first ligand LA of Formula I is disclosed. The compound is useful as an emitter in phosphorescent OLEDs.

Abstract: A compound including a ligand LA of Formula I is disclosed.

Abstract: A compound having a first ligand LA of Formula I, is disclosed. In the structure of Formula I, Z1 through Z7 are each independently C or N; ring B is a 5-membered or 6-membered ring; each RA, RB, and RC is independently hydrogen or one of a variety of substituents; any two substituents in RC may be joined or fused together to form a ring. In the compound, LA is complexed to a metal M, which is optionally coordinated to other ligands. In addition, ligand LA is optionally linked with other ligands to comprise a tridentate, tetradentate, pentadentate, or hexadentate ligand. Organic light emitting devices, consumer products, formulations, and chemical structures containing the compounds are also disclosed.

Abstract: The present disclosure is directed to a method and device for automatically predicting FFR based on images of vessel. The method for automatically predicting FFR based on images of a vessel. The method comprises a step of receiving the images of a vessel acquired by an imaging device. Then, a sequence of flow speeds at a sequence of positions on a centerline of the vessel is acquired by a processor. A sequence of first features at the sequence of positions on a centerline of the vessel are acquired by the processor, by fusing structure-related features and flow speeds and using a convolutional neural network. Then, a sequence of FFR at the sequence of positions is determined by the processor through using a sequence-to-sequence neural network on the basis of the sequence of first features.

Abstract: A neutral compound including a first ligand LA represented by Formula I or Formula II is disclosed.